Prothena Corporation plc
corporate_fare Company Profile
Prothena Corporation plc (NASDAQ:PRTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for PRTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for PRTA spans 8-K, 10-Q, 144, DEF 14A.
Recent high-impact activity:
- Prothena Q3 Loss Widens to 32 Cents a Share, Revenue Collapses 74%
- Prothena Q3 2026: Net Loss Narrows to $16.5M, Cash $272.2M, Burn Guidance Held
- BMS Terminates PRX019 License; Prothena Loses Up to $617.5M in Milestones
- Prothena Q2 2026: Net Loss Narrows to $18.6M as Restructuring Winds Down; Cash at $288M
- Prothena Posts Q2 Results, Highlights $3B in Potential Milestones from Partnered Pipeline
Financial Snapshot
Short Interest & Short Volume
15.69 days to coverFINRA reported short interest of 7,911,160 shares in PRTA as of the October 30, 2026 settlement, a 0.4% decrease from the prior period — about 15.7 days to cover at its recent average daily volume. On November 20, 2026, 44.9% of PRTA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.